Clinical trial
Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in…
NCT00331162 · Wake Forest University Health Sciences, Other · Completed
Key facts
| NCT number | NCT00331162 |
|---|---|
| Title | Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation |
| Official title | Alemtuzumab Versus Thymoglobulin Induction Therapy in Kidney and Pancreas Transplantation |
| Lead sponsor | Wake Forest University Health Sciences, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Graft Rejection |
| Intervention type | Drug |
| Interventions | Alemtuzumab, Anti-Thymocyte Globulin |
| Enrollment | 222 |
| Start date | Feb 1, 2005 |
| Primary completion | Nov 28, 2011 |
| Completion | Nov 28, 2011 |
| First posted | May 29, 2006 |
| Last update posted | Sep 6, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: